Hakan EMMUNGİL, Celal KARLIKAYA, İlker YILMAM, Bilkay SEREZ KAYA, Osman KULA

COVID-19’dan önce olsa idiopatik olarak tanımlanacak hayatı tehdit edici hemoptizi olgusu

2019 koronavirüs hastalığı (COVID-19), tıbbi paradigmayı biraz değiştirerek çok farklı klinik tablolar gösterebilen solunum yolu enfeksiyonu ile karakterizedir. İdiyopatik olarak tanımlanan hemoptizi %15’e kadar görülebilmektedir. Şu anda tıbbi koronavirüs literatüründe artan hemoptizi vakaları bildirilmektedir. Biz burada COVID-19 döneminden önce idiyopatik olarak tanımlanacak bir hemoptizi vakayı sunmaktayız. İlk klinik tablonun ardından olgu hayatı tehdit eden hemoptizi halini aldı. Vakayı klinik, patogenetik, terapötik ve klinik pratik yönleriyle kapsamlı bir şekilde inceledik. Biz de özellikle pandemi döneminde tüm hemoptizi olgularının prognozu belirsiz, yaşamı tehdit eden olası bir enfeksiyon hastalığı olarak değerlendirilmesi gerektiğini varsaydık

A life-threatening haemoptysis case that would have been defined as idiopathic before the COVID-19 era

A life-threatening haemoptysis case that would have been defined as idiopathic before the COVID-19 era The coronavirus disease 2019 (COVID-19) is characterized by respiratory infection which can show very different clinical pictures, somewhat changing medical paradigm. Hemoptysis defined as idiopathic can be seen as much as 15%. Currently, increasing hemoptysis cases are being reported in medical coronavirus literature. We here present a hemoptysis case that would be defined as idiopathic before the COVID-19 era. After the first clinical picture, the case turned into a life-threatening hemoptysis. We studied the case comprehensively as clinical, pathogenetical, therapeutic and clinical practical aspects. Thus, we hypothesized that especially in the pandemic era, all hemoptysis cases must be evaluated as a possible life threatening infectious disease with unpredictable prognosis.

PDF

___

1. Abal AT, Nair PC, Cherian J. Haemoptysis: aetiology, evaluation and outcome--a prospective study in a third-world country. Respir Med 2001; 95: 548-52.
2. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112: 440-4.
3. Kathuria H, Hollingsworth HM, Vilvendhan R, Reardon C. Management of life-threatening hemoptysis. J Int Care 2020; 8: 23.
4. Ibrahim WH. Massive haemoptysis: the definition should be revised. Eur Respir J 2008; 32(4): 1131.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of corona-virus disease 2019 in China. N Engl J Med 2020; NEJMoa2002032.
6. Xu XW, Wu XX, Jiang XG, Xu KJ, Ma CH, Li SB, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606.
7. Argun Barış S, Coşkun İS, Selvi G, Boyacı H, Başyiğit İ. Case series of COVID-19 presenting with massive hemoptysis. Turk Thorac J 2020; 21(6): 454-6.
8. Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A systematic scoping review of COVID‐19 during pregnancy and childbirth. Int J Gynaecol Obstet 2020; 150(1): 47-52.
9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
10. Huang C, Wang Y, Li X, Lili R, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
12. Peys E, Stevens D, Weygaerde YV, Malfait T, Hermie L, Rogiers P, et al. Haemoptysis as the first presentation of COVID-19: a case report. BMC Pulm Med 2020; 20: 275.
13. Casey K, Iteen A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med 2020; 38(7): 1544.e1-1544.e3.
14. Bond D, Vyas H. Viral Pneumonia and hemoptysis. Crit Care Med 2001; 29(10): 2040-1.
15. Magro C, Ali N, Williams JD, Allen JA, Ross Jr P. Cytomegalovirus-associated pulmonary septal capillary injury sine inclusion body change: a distinctive cause of occult or macroscopic pulmonary hemorrhage in the immunocompetent host. Appl Immunohistochem Mol Morphol 2005; 13(3): 268-72.
16. von Ranke FM, Zanetti G, Hochhegger B, Hochhegger B, Marchiori E, et al. Infectious diseases causing diffuse alveolar hemorrhage in immunocompetent patients: a stateof-the-art review. Lung 2013; 191(1): 9-18.
17. Herry I, Cadranel J, Antoine M, Meharzi J, Michelson S, Parrot A, et al. Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: a new clinical entity? Clin Infect Dis 1996; 22(4): 616-20.
18. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration 2010; 80(1): 38-58.
19. Aoshiba K, Nagai A. Oxidative stress, cell death, and other damage to alveolar epithelial cells induced by cigarette smoke. Tob Induc Dis 2003; 1: 219-26.
20. McGonagle D, Bridgewood C, Ramanan AV, Meaney JFM, Watad A. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021; 3(3): e224-e33.